[Special Stock] Encell Shows Strength on Asian Technology Transfer of Stem Cell Therapy

Encell is showing strong performance following the news of the technology transfer of 'EN001 (mesenchymal stem cell therapy)' to six Asian countries.

As of 10:21 AM on the 10th, Encell is trading on the KOSDAQ market at 30,150 KRW, up 3,500 KRW (13.13%) from the previous close.

The current trading volume is 1.27 million shares, with a trading value of approximately 38.9 billion KRW.

Encell announced after the market closed on the 9th that it signed a contract to transfer the technology of the mesenchymal stem cell therapy EN001 to six Asian countries, including Hong Kong's Lucy Biotech. The contract consists of a signing fee of 19.5 million USD (25.4 billion KRW) and royalties, with an advance payment of 1.5 million USD (1.9956 billion KRW).